JPRN-UMIN000027689已完成未知
Therapeutic response to enzyme-targeting radiosensitization treatmentusing using hydrogen peroxide and hyaluronic acid - Therapeutic response to enzyme-targeting radiosensitization treatmentusing using hydrogen peroxide and hyaluronic acid
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Severe complication 2)History of hypersensitivity to hyaluronic acid 3)History of hypersensitivity to H2O2 4)investigator judged ineligible
研究者
相似试验
暂停
Unknown
Radiobiological characterisation and therapy monitoring of oligo- compared to polymetastatic breast cancerC50Malignant neoplasm of breastDRKS00031591Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Hamburg-Eppendorf50
终止
1 期
Peptide Receptor Radionuclide Therapy administered to Participants withMeningioma with 67Cu-SARTATE™Cancer - BrainCancer - Head and neckCancer - Other cancer typesMeningiomaACTRN12618000309280Clarity Pharmaceuticals Ltd.5
进行中（未招募）
1 期
START-NET: A randomized clinical trial to compare personalized vs non-personalized radionuclide therapy with 177Lu-DOTATOCPatients with SSTR+, advanced, progressive NET Grade 1-3 of any origin for whom Peptide-receptor radionuclide therapy, PRRT, is considered the mostappropriate treatment option in relation to other approved or available investigational agents for the specific tumor subtype.MedDRA version: 21.0Level: LLTClassification code 10062476Term: Neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-002218-15-SERegion Skåne300
进行中（未招募）
不适用
Receptor radionuclide therapy with [177Lu-DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial. - NDcancer patientsMedDRA version: 9.1Level: LLTClassification code 10028980Term: NeoplasmEUCTR2007-005517-20-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
进行中（未招募）
不适用
Peptide Receptor Radionuclide Therapy (PRRT) in advanced gastro-entero-pancreatic Neuroendocrine TumorsAdvanced gastro-entero-pancreatic Neuroendocrine Tumors, FDG-PET negative patientsMedDRA version: 16.0Level: HLGTClassification code 10014713Term: Endocrine neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-003165-34-ITIRCCS-IRST of Meldola